Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|June 27, 2022
Dr. Zhang on frontline treatment selection factors in metastatic kidney cancer
Author(s)Urology Times staff
“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.
Advertisement
Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses factors she uses in the clinic to decide among the evolving treatment options in the frontline setting for patients with metastatic renal cell carcinoma.
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5